Lupin Fair Value
Lupin (LUPIN) average fair value is ₹1923.2 across 8 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹2276.4 (-15.52%), fair value range ₹495.05–₹6586.39. See Lupin P/B ratio trends to compare market price against book value per share.
Fair Value Analysis Export
LUPIN Fair Value vs Current Price — Valuation Summary
LUPIN average fair value, fair value range, price gap and valuation status across 8 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Earnings Growth Model (PEG), Peter Lynch Fair Value, Benjamin Graham Number, Discounted Cash Flow (DCF). For live price and a broader fundamental view, visit LUPIN screener.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Earnings Growth Model (PEG)
Peter Lynch Fair Value
Benjamin Graham Number
Discounted Cash Flow (DCF)
LUPIN Fair Value Analysis — Data Sources & Coverage
Lupin financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. Examine LUPIN earnings for recent quarterly revenue, profit and EPS trends.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
LUPIN vs Healthcare Sector Peers — P/E, P/B & Market Cap
Lupin P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Accretion Pharmaceuticals | ACCPL | 13.72 | 2.43 | ₹131 |
| Par Drugs & Chemical | PAR | 8.67 | 1.01 | ₹111 |
| Jeena Sikho Lifecare | JSLL | 40.02 | 22.33 | ₹7,891 |
| Auro Laboratories | AUROLAB | 91.49 | 3.91 | ₹165 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.